Clinical Trials Logo

Efficacy and Safety clinical trials

View clinical trials related to Efficacy and Safety.

Filter by:

NCT ID: NCT06383078 Not yet recruiting - Efficacy and Safety Clinical Trials

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Start date: April 20, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as adjuvant therapy in patients with resected pancreatic cancer.

NCT ID: NCT06351735 Not yet recruiting - Efficacy and Safety Clinical Trials

Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis

Start date: August 1, 2024
Phase:
Study type: Observational

Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, affects motor neurons, causing progressive muscle atrophy and weakness. Current treatments are ineffective, with most patients dying within 3-5 years of diagnosis. The disease's exact cause is unclear, but factors such as oxidative stress and protein abnormalities are implicated. Abnormal protein deposits and neurotoxic factors in the brain and spinal cord contribute to ALS pathology. Recent research on the brain's glymphatic-lymphatic system suggests impaired waste clearance may exacerbate ALS. Restoring drainage connections between cervical lymphatic vessels and veins could potentially alleviate neurodegenerative disease progression.

NCT ID: NCT06218004 Not yet recruiting - Efficacy and Safety Clinical Trials

Envafolimab Combined With Chemotherapy in Neoadjuvant and Conversion Therapy for Head and Neck Squamous Cell Carcinoma

Start date: January 25, 2024
Phase: Phase 2
Study type: Interventional

This study is a prospective clinical study. The purpose is to explore the efficacy and safety of Envafolimab combined with chemotherapy for neoadjuvant treatment or conversion treatment of locally advanced head and neck squamous cell carcinoma, and to observe the correlation between the immune microenvironment and the efficacy of immune checkpoint inhibitors, genetic changes and the efficacy in head and neck squamous cell carcinoma .

NCT ID: NCT06202456 Completed - Efficacy and Safety Clinical Trials

A Phase IV Study of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver

Start date: May 13, 2020
Phase: Phase 4
Study type: Interventional

An open Label, Single-arm, Multicenter phase IV study; There was a 2-week screening period and a 12-week / 24-week treatment period

NCT ID: NCT06194188 Active, not recruiting - Efficacy and Safety Clinical Trials

A Phase 2 Clinical Study of CU-20401

Start date: January 2, 2024
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase Ⅱ clinical study to evaluate the efficacy, safety, and immunogenicity of CU-20401 for Injection in a population with moderate to severe contour elevation or over-fullness due to SMF accumulation.

NCT ID: NCT05532111 Not yet recruiting - Efficacy and Safety Clinical Trials

Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

1. Main purpose: To evaluate the efficacy and safety of rituximab combined with tacrolimus in the treatment of intermediate and high-risk primary membranous nephropathy 2. Secondary research purposes: To describe the survival of patients with intermediate and high-risk primary membranous nephropathy treated with rituximab combined with tacrolimus; To describe renal survival in patients with intermediate and high-risk primary membranous nephropathy treated with rituximab combined with tacrolimus; 3. Exploratory research purposes: Feasibility of glucocorticoids-free therapy (rituximab combined with tacrolimus) in the treatment of intermediate and high-risk primary membranous nephropathy

NCT ID: NCT05481775 Withdrawn - Efficacy and Safety Clinical Trials

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, randomized, controlled phase II clinical study for evaluating anlotinib combined with concurrent chemoradiotherapy followed by consolidation immunotherapy versus concurrent chemoradiotherapy followed by consolidation immunotherapy in locally advanced, unresectable NSCLC.

NCT ID: NCT04870606 Completed - Efficacy and Safety Clinical Trials

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

Start date: March 5, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.

NCT ID: NCT04759534 Active, not recruiting - Clinical trials for Heterozygous Familial Hypercholesterolemia

Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia

Start date: September 10, 2020
Phase: Phase 3
Study type: Interventional

This study plans to enroll several patients with heterozygous familial hypercholesterolemia, randomly assigned to different dose groups, and randomly receiving subcutaneous injection of IBI306150 mg or placebo every two weeks: or subcutaneous injection of IBI306 450mg every four weeks (n=49) or placebo (n=25) treatment, treatment lasted for 12 weeks. During randomization, the LDL-C level (<4.8mmol/L or ≥4.8mmol/L) observed during the screening period visit (VI), and whether ezetimibe was used for stratification. After 12 weeks, each group entered the 12-week open-period treatment, in which subjects in the IBI306 group continued to receive IBI306 treatment, and subjects in the placebo group stopped using placebo and received IBI306 treatment. The exploratory endpoint is the population pharmacokinetic characteristics of IBI306 in Chinese heterozygous familial hypercholesterolemia population.

NCT ID: NCT04518501 Recruiting - Efficacy and Safety Clinical Trials

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Start date: July 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was only 3-4% in homologous recombination proficiency patients with PARPi therapy. New treatments are urgently needed to improve patient outcomes. To explore the efficacy and safety of Fuzuloparib in combination with Arsenic trioxide therapy in platinum-resistance relapsed Ovarian cancer patients.